Cita APA (7a ed.)
Rhea, L., Daniels, M., Sabo, R., & Poklepovic, A. S. (2023 Supplement 16). Tumor-informed circulating tumor DNA (TI-ctDNA) based molecular residual disease (MRD) detection and relapse risk for patients with stage II-IV melanoma in surgical remission: A single center experience. Journal of Clinical Oncology, 41, 9572-9573.
Cita Chicago Style (17a ed.)
Rhea, Logan, Megan Daniels, Roy Sabo, y Andrew Stewart Poklepovic. "Tumor-informed Circulating Tumor DNA (TI-ctDNA) Based Molecular Residual Disease (MRD) Detection and Relapse Risk for Patients with Stage II-IV Melanoma in Surgical Remission: A Single Center Experience." Journal of Clinical Oncology 41 (2023 Supplement 16): 9572-9573.
Cita MLA (9a ed.)
Rhea, Logan, et al. "Tumor-informed Circulating Tumor DNA (TI-ctDNA) Based Molecular Residual Disease (MRD) Detection and Relapse Risk for Patients with Stage II-IV Melanoma in Surgical Remission: A Single Center Experience." Journal of Clinical Oncology, vol. 41, 2023 Supplement 16, pp. 9572-9573.
Precaución: Estas citas no son 100% exactas.